An Open-Label Study to Investigate the Regional Brain Kinetics of the Positron Emission Tomography Ligand 11C-MK-3168 and the Blocking of the Retention of the Ligand in the Human Brain by JNJ-42165279
Latest Information Update: 06 Nov 2021
At a glance
- Drugs JNJ 42165279 (Primary)
- Indications Anxiety disorders
- Focus Pharmacodynamics
- Sponsors Janssen Research & Development
Most Recent Events
- 24 Sep 2014 Status changed from recruiting to completed as reported by ClinicalTrials.gov record.
- 13 Jul 2014 New trial record